Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, derived from the immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg) through C-terminal extension with Pro-Gly-Pro. Unlike classical benzodiazepines, Selank has been characterized in preclinical models for anxiolytic activity without dependence liability, sedation, or anticonvulsant effects—suggesting a mechanistically distinct interaction with inhibitory neurotransmission. This article reviews current evidence for GABA-A receptor interaction, BDNF pathway modulation, and the pharmacological profile emerging from rodent and limited human research data.
GABA-A Receptor Interaction: Modulation Without Direct Binding
GABA-A receptors (γ-aminobutyric acid type A) are ligand-gated chloride channels with a pentameric structure (typically 2α, 2β, 1γ subunit composition) providing multiple allosteric sites for benzodiazepines, barbiturates, neurosteroids, and anesthetic agents. Selank does not demonstrate direct binding to the benzodiazepine site (Bz site, in the α-γ interface) in classical radioligand competition assays. Instead, evidence from Russian research groups suggests Selank increases GABAergic tone indirectly: it inhibits enkephalin-degrading aminopeptidases (prolyl endopeptidase, neprilysin), increasing endogenous enkephalin availability, which then modulates GABAergic interneuron activity through delta-opioid receptor (DOR)-mediated disinhibition of GABA release. This indirect mechanism may explain the absence of sedation: direct GABA-A agonism (benzodiazepines) produces sedation via cerebellar and thalamic α1-subunit-containing receptors, whereas Selank's indirect potentiation may preferentially modulate limbic circuits (α2/α3-containing receptors mediating anxiolysis) without engaging the sedative pathway. Electrophysiological recordings in rat cortical slices show Selank (100 nM–1 µM) increases inhibitory postsynaptic potential (IPSP) frequency without altering amplitude—consistent with presynaptic modulation of GABAergic interneuron activity rather than direct postsynaptic receptor sensitization.
BDNF/TrkB Pathway: Neuroplasticity Dimension of Selank's Profile
BDNF (brain-derived neurotrophic factor) signals through TrkB (tropomyosin receptor kinase B), activating downstream PI3K/Akt, MAPK/ERK, and PLCγ/CaMKII cascades that regulate synaptic plasticity, dendritic complexity, and neuronal survival. Selank has been shown to increase hippocampal BDNF mRNA in rats by approximately 1.4–1.8-fold (qRT-PCR, 250 µg/kg intranasal, 5 days) and to increase TrkB phosphorylation (Tyr816) at 2h post-injection in hippocampal tissue extracts. This BDNF upregulation is relevant because chronic stress models reduce hippocampal BDNF—a finding consistently correlated with anxiety- and depression-like behaviors in rodents—and Selank's BDNF induction may underpin the persistence of anxiolytic effects observed beyond its peptide half-life (~12–15 minutes in plasma). The BDNF/TrkB → ERK → CREB cascade also drives expression of Arc, synapsin-1, and AMPA receptor subunits (GluA1), which collectively strengthen synaptic connections—a cellular correlate of the improved associative memory reported in Selank-treated rodents on Morris Water Maze and passive avoidance paradigms.
Comparative Profile vs Benzodiazepines and Other Anxiolytics
The pharmacological profile differentiating Selank from benzodiazepines includes: (1) absence of sedation at anxiolytic doses in rodents (elevated plus maze anxiety index reduced ~30–40% at 250 µg/kg intranasal without changes in locomotor activity); (2) no withdrawal or rebound anxiety following 14-day administration and cessation; (3) absence of tolerance to anxiolytic effects in repeated-dose paradigms; (4) mild cognitive-enhancing effects (improved novel object recognition, passive avoidance) rather than cognitive impairment typical of benzodiazepines. Compared to buspirone (5-HT1A agonist), Selank produces more rapid-onset anxiolysis (acute vs. 2–4 weeks for buspirone) with comparable magnitude effect in elevated plus maze. Selank does not displace 5-HT1A or D2 receptor radioligands, excluding those mechanisms as primary drivers.
Research Formulation Parameters and Administration Routes
Selank's peptide structure renders it susceptible to rapid proteolytic degradation in peripheral plasma (~12 min half-life); intranasal administration bypasses first-pass hepatic/enteral degradation and achieves direct olfactory epithelium-to-CNS delivery via trigeminal and olfactory nerve routes. Pharmacokinetic studies in rats (radiolabeled Selank, 25 µg intranasal) show peak CNS concentration at ~20–30 minutes, declining to baseline by 90 minutes—but downstream BDNF and receptor changes persist significantly longer.
- Dose range (rodent): 100–500 µg/kg intranasal or intraperitoneal
- Key assays: elevated plus maze, open field, novel object recognition; BDNF ELISA (hippocampus), TrkB western blot, cortical EEG gamma power
- Purity standard: HPLC >99%, acetate salt form, lot-traceable CoA; store lyophilized at −20°C with desiccant
- Stability note: Selank in aqueous solution degrades significantly within 72h at 4°C; reconstitute immediately before use
All compounds described are for laboratory and research use only. They are not approved for therapeutic, diagnostic, or clinical use in humans. Researchers should comply with applicable institutional and regulatory requirements for peptide research materials.